Delivery Order SPE2DB22D2206-SPE2DB25FDU85

Award Date 10/16/24
Potential Completion Date 10/17/24
Potential Value $3.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $25,055.93 firm fixed-price delivery order is for the supply of Rexulti 1 mg tablets, a prescription medication. The contract has a completion date of February 21, 2025 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,220.15 firm fixed-price delivery order is for the supply of Rexulti 0.5 mg tablets. The contract, which does not have a set-aside designation, has an ultimate completion date of August 22, 2024. In addition to this specific delivery order, AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC)...
This federal contract award, valued at $19,290.20, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order contract to supply 4,568,062,178 units of the prescription medication Rexulti 2 mg tablet. The contract has a firm fixed price and an ultimate completion date of April 29, 2025. This order is not set aside and appears to be part of a larger Indefinite Delivery...
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $14,470.83 firm fixed-price contract is for the supply of the prescription drug Rexulti 2 mg tablets, with a period of performance through April 2025. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, from the Defense Logistics Agency (DLA), a defense agency. The contract is a delivery order with a firm fixed price valued at $10,748.27 and a completion date of June 6, 2025. The contract is for the supply of Rexulti 2 mg tablets, a prescription medication. Amerisourcebergen Drug Corp is the prime contractor and there is no set-aside designation, indicating open...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,925.61 firm fixed price delivery order is for the supply of Rexulti 2 mg tablets to support federal healthcare programs. The contract has a completion date of November 14, 2024 and is not designated with any set-aside requirements, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite...
This federal contract award, valued at $16,730.66, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the medication Rexulti 0.5 mg tablet, with an ultimate completion date of April 30, 2025. The contract is a firm fixed-price, non-set-aside award, indicating open competition. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC)...
This federal contract award, valued at $12,170.48, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of the medication Rexulti 2 mg tablet, a treatment for certain mental health conditions. This is a firm-fixed-price delivery order contract with an ultimate completion date of April 21, 2025. The contract is not set aside for any specific type of business....
This federal contract award, valued at $3,315.58, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Rexulti 1 mg tablets and is a firm-fixed-price delivery order with an ultimate completion date of October 30, 2023. The contract is not designated as a set-aside and was awarded as part of Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award to AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical distribution company AmerisourceBergen Corporation, is a delivery order valued at $11,081.84 for the supply of the pharmaceutical product Rexulti 2 mg tablets. The award was made by the Defense Logistics Agency (DLA), a defense agency of the U.S. Department of Defense, and has a period of performance through March 27, 2024. This delivery order is placed under a larger indefinite delivery...
  • SPE2DB22D2206
    Indefinite Delivery Contract
  • SPE2DB22D2206-SPE2DB25FDU85
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,606.39 firm fixed-price delivery order is for the supply of 4,566,121,371 units of the prescription drug Rexulti 2 mg tablet. The contract has an ultimate completion date of October 17, 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. No set-aside designation was used for this award. The contract award demonstrates AmerisourceBergen's critical role in supplying essential medical commodities, including specialty medications, to federal government agencies.

Generated 1/15/25, 9:23 AM